Table 3.
P-scores for comparison between treatments for safety parameters.
| Parameter | Placebo | Modafinil 200 mg | Modafinil 400 mg | Pitolisant | Solriamfetol |
|---|---|---|---|---|---|
| Overall safety (Risk ratio) | 0.93 | 0.39 | 0.29 | 0.69 | 0.21 |
| Ranking | 1 | 3 | 4 | 2 | 5 |
| Overall safety (Z-score) | 0.91 | 0.37 | 0.29 | 0.81 | 0.12 |
| Ranking | 1 | 3 | 4 | 2 | 5 |
| Cardiovascular safety (Risk ratio) | 0.7 | 0.42 | 0.53 | 0.72 | 0.14 |
| Ranking | 2 | 4 | 3 | 1 | 5 |
| Cardiovascular safety (Z-score) | 0.67 | 0.4 | 0.51 | 0.8 | 0.13 |
| Ranking | 2 | 4 | 3 | 1 | 5 |
| All TEAEs | 0.94 | 0.47 | 0.31 | 0.56 | 0.22 |
| Ranking | 1 | 3 | 4 | 2 | 5 |
| SAEs | 0.8 | NA | 0.35 | 0.52 | 0.32 |
| Ranking | 1 | – | 3 | 2 | 4 |
| Headache | 0.83 | 0.31 | 0.29 | 0.81 | 0.25 |
| Ranking | 1 | 4 | 3 | 2 | 5 |
| TEAEs (not headache) | 0.91 | 0.68 | 0.13 | 0.35 | 0.43 |
| Ranking | 1 | 2 | 5 | 4 | 3 |
| Systolic blood pressure | 0.67 | 0.3 | 0.49 | 0.74 | 0.3 |
| Ranking | 2 | 4 | 3 | 1 | 4 |
| Diastolic blood pressure | 0.59 | 0.5 | 0.4 | 0.78 | 0.23 |
| Ranking | 2 | 3 | 4 | 1 | 5 |
| Heart rate | 0.73 | NA | NA | 0.75 | 0.02 |
| Ranking | 2 | – | – | 1 | 3 |
For each parameter, a P-score highlighted in yellow signifies a significant one-sided benefit of a treatment compared with a blue-highlighted treatment: a P-score closer to 1 indicates relative superiority.
SAE, serious adverse event; TEAE, treatment emergent adverse event.
Drugs are ranked by P-score for each parameter.